Latest Financial Position News

BSA Limited’s Q1 FY2026 results reveal a sharp revenue drop following the expiration of its key nbn contract, alongside a major workforce reduction and strategic pivot.

Race Oncology has filed pivotal patents on the active (E,E)-bisantrene isomer, potentially extending its drug exclusivity by two decades, while advancing its Phase 1 clinical trial and maintaining a strong cash position.

Antilles Gold advances its Cuban mining ambitions with a binding EPC contract signed and construction slated to begin early next year at the Nueva Sabana copper-gold project.

Jindalee Lithium reported a challenging quarter with over A$2 million in cash outflows but bolstered its funding position with a recent $8 million share placement, extending its operational runway.

Australian Gold and Copper Ltd has significantly expanded its South Cobar exploration footprint through key acquisitions and reported strong high-grade drilling results at its Achilles deposit, underpinning its growth strategy.

Percheron Therapeutics reports encouraging phase I clinical results for HMBD-002, confirming safety and early efficacy signals, while gearing up for a multi-arm phase II trial in 2026.

Venus Metals Corporation reports a significant update to its Sandstone gold resource, formalizes a joint venture with IGO at Bridgetown-Greenbushes, and reveals promising zinc and indium mineralisation at Youanmi.

Strickland Metals delivers robust drilling results at its Serbian Rogozna Project, revealing new high-grade copper-gold zones and expanding gold mineralisation footprints, while completing the sale of its Yandal Project to Gateway Mining.

EQ Resources Limited reported a robust Q1 FY2026 with soaring tungsten prices, operational upgrades, and significant capital raises to fuel mine expansions.

Taiton Resources has completed key soil sampling programs targeting gold and rare earth elements at its South Australian projects, alongside heritage surveys and regulatory steps, supported by a recent $2 million capital raise.

Zoono Group Limited reports strong progress in its shelf-life extension technology with 50 active trials worldwide and anticipates its first significant sales this quarter, supported by fresh funding and expanding market interest.

Hydralyte USA reported a 6% year-on-year sales increase in Q3 FY25 alongside a significant 42% reduction in operating cash burn, driven by a streamlined US-focused model and new product launches in brain and gut health.